Trans Tasman Radiation Oncology Group

5 in Phase 3

Quick facts

Phase 3 pipeline

Long Course Adjuvant Chemotherapy · Oncology
Long course adjuvant chemotherapy delivers extended cycles of cytotoxic chemotherapy after primary cancer treatment to eliminate residual disease and reduce recurrence risk.
Post radiotherapy commencement of anastrozole · Oncology
Anastrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.
Pre-radiotherapy commencement of anastrozole · Oncology
Anastrozole inhibits aromatase, reducing estrogen levels in postmenopausal women.
Short Course Adjuvent Chemotherapy · Oncology
Short Course Adjuvent Chemotherapy involves administering a limited course of chemotherapy to enhance the effectiveness of radiation therapy.
Sorbolene · Other

Phase 2 pipeline

Etoposide with Carboplatin or Cisplatin

Phase 1 pipeline

Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Trans Tasman Radiation Oncology Group

What is Trans Tasman Radiation Oncology Group's pipeline?

Trans Tasman Radiation Oncology Group has 5 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Long Course Adjuvant Chemotherapy, Post radiotherapy commencement of anastrozole, Pre-radiotherapy commencement of anastrozole, Short Course Adjuvent Chemotherapy.

Sector hub: All tracked pharma companies